- Details
- Sam Chang and Stephen Williams discuss the ongoing SunRISe-2 trial, a phase three study targeting muscle-invasive bladder cancer (MIBC). Dr. Williams details the trial's innovative approach using TAR-200, a device for sustained gemcitabine release directly into the bladder, combined with cetrelimab, a PD-1 antibody. The goal is to offer a bladder-preserving treatment option for patients who are in...
|
- Details
- Ashish Kamat hosts a discussion with Matthew Galsky and Neal Shore on the latest advancements in antibody-drug conjugates (ADCs) for bladder cancer. Dr. Galsky provides an overview of ADCs, highlighting the components and mechanisms of enfortumab vedotin and sacituzumab govitecan, and discusses promising results from recent trials. He also touches on emerging targets like HER2 and their potential...
|
- Details
- Sam Chang interviews Karim Chamie about pivotal clinical trials in urothelial carcinoma presented at AUA 2024. Dr. Chamie discusses the MoonRISe-1 trial, a Phase III study on TAR-210 (an erdafitinib intravesical delivery system) for intermediate-risk non-muscle-invasive bladder cancer, highlighting its innovative approach and potential to change the treatment landscape. He also reviews the SunRISe...
|
- Details
- Sam Chang interviews Woodson Smelser to discuss takeaways from the AUA Annual Meeting in urothelial carcinoma, highlighting the rapid advancements in non-muscle invasive bladder cancer therapies. He emphasizes the importance of new FDA-approved agents like Pembrolizumab, Nadofaragene, and Nogapendekin. Dr. Smelser also reviews clinical trials, such as the TAR-200 device and the CG0070 adenovirus....
|
- Details
- Sam Chang interviews Neal Shore about the KEYNOTE-992 trial comparing immunotherapy combined with chemoradiation to standard trimodality therapy for muscle-invasive bladder cancer. Dr. Shore explains that the trial evaluates Pembrolizumab with chemoradiation versus placebo with chemoradiation in patients suitable for bladder-sparing approaches. He emphasizes the importance of offering bladder-pres...
|
- Details
- Ashish Kamat hosts a discussion with Matt Galsky and Neal Shore on the latest advancements in bladder cancer treatment, focusing on immunotherapy for advanced bladder cancer and the associated survival benefits. He emphasizes the importance of recognizing and managing immune-related toxicities. Dr. Shore discusses the application of immunotherapy in earlier stages of disease, mentioning pembrolizu...
|
- Details
- Ashish Kamat welcomes Petros Grivas to discuss the current state and future prospects of treating invasive bladder cancer with neoadjuvant chemotherapy or immunotherapy followed by local therapy. Dr. Grivas emphasizes the current standard of care involving neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy or chemoradiation. He highlights promising clinical trials, such as RET...
|
- Details
- Pat Hensley discusses first-line systemic therapy selection for advanced urothelial carcinoma with Karima Oualla and Shilpa Gupta. They highlight cisplatin-based chemotherapy as the traditional mainstay but shift focus to the EV-302 trial, which explores enfortumab vedotin (EV) and pembrolizumab (pembro) as a new first-line combination. Dr. Oualla explains the mechanisms and significant efficacy o...
|
- Details
- Alicia Morgans hosts a discussion with Massimo Alfano and Filippo Pederzoli on the promising link between the stool microbiome and the effectiveness of neoadjuvant pembrolizumab in treating muscle-invasive bladder cancer. This intriguing connection explores how the microbiome could serve as a predictive biomarker for immunotherapy outcomes. Dr. Alfano credits the genesis of their research to prior...
|
- Details
- Alicia Morgans introduces Jonathan Rosenberg who discusses the EV-302 trial. This Phase III trial, which Dr. Rosenberg explains, involved a comparison between enfortumab vedotin (EV) combined with pembrolizumab and traditional chemotherapy for untreated metastatic urothelial cancer patients. The results were striking, with a notable improvement in both progression-free and overall survival for pat...
|
